Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

635
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
635
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Asthma and Rheumatoid Arthritis: Conundrum Still Unsolved.

The journal of allergy and clinical immunology. In practice·2026
Same author

Liquid Biopsy in Cancer: The Importance of Integrating Bioinformatics Approaches Towards the Development of a Personalized Molecular Profile.

Cancers·2026
Same author

The Critical Role of Transcription Factor RUNX2 in Bone Mechanobiology.

Cells·2026
Same author

Harnessing TP53 mutational status to enhance prognostic precision and therapeutic effectiveness in head and neck squamous cell carcinoma.

Oral oncology·2026
Same author

Malnutrition and Sarcopenia in Patients with Neuroendocrine Tumors: A Comprehensive Review of Evidence.

Biomolecules·2025
Same author

Comprehensive Liquid Biopsy Approaches for the Clinical Management of Lung Cancer Using Multiple Biological Matrices.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Apr 27, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K

Bromodomains: pockets with therapeutic potential.

Kostas A Papavassiliou1, Athanasios G Papavassiliou1

  • 1Department of Biological Chemistry, University of Athens Medical School, 11527 Athens, Greece.

Trends in Molecular Medicine
|July 3, 2014
PubMed
Summary

Bromodomain (BRD) inhibitors targeting the acetyl-lysine binding pocket show promise for treating cancer and inflammatory diseases. Several BRD inhibitors are advancing in clinical trials, indicating significant therapeutic potential.

Keywords:
bromodomain inhibitorbromodomain pockettherapeutic targettranscriptional regulation

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.2K
Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes
07:41

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes

Published on: October 2, 2017

7.8K

Related Experiment Videos

Last Updated: Apr 27, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.2K
Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes
07:41

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes

Published on: October 2, 2017

7.8K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Bromodomains (BRDs) are protein modules that recognize acetylated lysine (KAc) residues.
  • Dysregulation of BRD proteins is implicated in various diseases, including cancer and inflammatory conditions.
  • Targeting the KAc binding pocket of BRDs offers a therapeutic strategy.

Purpose of the Study:

  • To review the development and therapeutic potential of small molecule BRD inhibitors.
  • To highlight the role of BRD inhibition in treating diverse diseases.
  • To assess the progress of BRD inhibitors in clinical trials.

Main Methods:

  • Literature review of studies on bromodomain inhibitors.
  • Analysis of preclinical and clinical data for BRD-targeted therapies.
  • Examination of the mechanism of action of BRD inhibitors.

Main Results:

  • Small molecule inhibitors targeting the BRD KAc binding pocket have been developed.
  • BRD inhibition demonstrates therapeutic potential across cancer, inflammation, obesity, cardiovascular, and neurological disorders.
  • Five BRD inhibitors are currently undergoing clinical trials.

Conclusions:

  • Bromodomain inhibition represents a promising therapeutic avenue for numerous diseases.
  • The advancement of BRD inhibitors into clinical trials signifies a maturing field with high potential.
  • Further research and development in BRD-targeted therapies are warranted.